Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Geriatric Assessment-guided therapy modification and outcomes in patients with non-metastatic gastroesophageal cancer: a retrospective cohort study.

ESMO gastrointestinal oncology·2026

Same author

Integrating multimodal prehabilitation into enhanced recovery after surgery programs (MPhERAS) for elderly patients: a systematic review and meta-analysis of randomized controlled trials and cohort studies.

Techniques in coloproctology·2025

Same author

<i>Meso</i>-Modified Porphyrinoids: Stimuli-Driven Conformational Plasticity, Modulation of π-Conjugation, and Bis-Rh(I) Complexation.

Inorganic chemistry·2025

Same author

Nonalternant Acenaphthylene-Fused Carbaporphyrins: Topological Modulation of π-Delocalization, (Anti)aromaticity, and B<sup>III</sup> Coordination.

Organic letters·2025

Same author

Siamese Twin Homocarbaporphyrin Dimer: Nonplanar Architecture, Localized Conjugation and Bis-B<sup>III</sup> Complex.

Chemistry, an Asian journal·2025

Same author

<i>E</i>-Stilbene-Imprinted Cyclic Diphyrin and Its B<sup>III</sup> Complex.

Organic letters·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.

P Rujkijyanont¹, C Morris, G Kang

¹Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.

Blood Cancer Journal

|September 3, 2013

Summary

A novel risk-adapted donor lymphocyte infusion (DLI) strategy effectively converts mixed chimerism to full donor chimerism post-stem cell transplant, significantly reducing leukemia relapse and graft-versus-host disease (GvHD) risks.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Related Experiment Videos

Last Updated: May 8, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Area of Science:

Hematology
Immunology
Oncology

Background:

Donor lymphocyte infusion (DLI) is a standard treatment for leukemia relapse after stem cell transplantation.
However, DLI efficacy is limited in advanced relapse, with a high risk of severe graft-versus-host disease (GvHD).

Purpose of the Study:

To develop and evaluate a novel risk-adapted DLI strategy for improving outcomes in patients with mixed chimerism post-stem cell transplantation.
To minimize leukemia relapse and GvHD while maximizing overall survival.

Main Methods:

A risk-adapted DLI strategy was implemented, involving pre-emptive DLI at mixed chimerism, dose adjustments based on donor type, real-time chimerism monitoring, and DLI cessation upon achieving full chimerism.
The study included 38 patients with mixed chimerism who received 178 DLIs.

Main Results:

Eighty-six-point-eight percent (33/38) of patients achieved increased donor chimerism, with 78.9% (30/38) reaching 100% donor chimerism.
Patients with fully corrected chimerism showed a significantly lower cumulative incidence of relapse (P=0.00004) and higher overall survival (P=0.0003) compared to those with mixed chimerism.
Only 13.2% of patients developed acute grade III-IV GvHD, with no associated mortality.

Conclusions:

The risk-adapted DLI strategy effectively converts mixed chimerism to full donor chimerism.
This approach significantly reduces the risk of leukemia relapse, GvHD, and mortality in patients undergoing stem cell transplantation.
The strategy offers a safer and more effective method for managing mixed chimerism post-transplant.